1. Real-life Experience inC.C.HThe Role of Anti-IgE Therapy InAsthma Management M.D Alex Tsai

2. Journal of Asthma and Allergy 2011:4 3. N Engl J Med 2006;354:2689-95. 4. Omalizumab Characteristics Murine CDRs*Humanized mAb against IgE (< 5% of molecule)Bindscirculating IgE regardless of specificityForms small, biologically inertIgG1 kappa Omalizumab:IgE complexesHuman frameworkDoesnot activate complement(> 95% of molecule)*CDR = complementarity-determining regionAdapted with permission from Boushey H. J Allergy Clin Immunol. 2001;108:S77-S83. 5. Airway Inflammation in Asthma 6. Anti-IgE .. 7. omalizumabChang TW et al. JAllergy ClinImmunol2006;117:1203- 8. INNOVATE: INvestigatioN of Omalizumabin seVere Asthma TrEatment A 28-week randomized double-blind, placebo-controlledstudy to assess the efficacy and safety of add-onomalizumab therapy in patients with severe persistentasthma (GINA 2002) inadequately controlled despite high dosesof ICS (> 1000 g/day BDP) and LABA Humbert et al., Allergy 2005 9. INNOVATE: Omalizumab reduces clinically significant exacerbationsExacerbationsSevere exacerbations1.00.5 Exacerbations [/patient-28 wks.]0.48- 26% 0.91 - 50% 0.4 p